Track topics on Twitter Track topics that are important to you
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Pipeline Review, H1 2019
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 Integrin beta3 3 or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alphaIIb/beta3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.
Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 15 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Infectious Disease and Immunology which include indications Breast Cancer, Wet Neovascular / Exudative Macular Degeneration, Coronary Artery Disease CAD Ischemic Heart Disease, Diabetic Nephropathy, Glioblastoma Multiforme GBM, Metastatic Melanoma, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Wounds, Diabetic Macular Edema, Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma Kahler Disease, Myocardial Infarction, Primary Sclerosing Cholangitis, Prostate Cancer, Rheumatoid Arthritis, Sepsis and Staphylococcus Aureus Septicaemia.
The latest report Integrin Beta 3 Pipeline Review, H1 2019, outlays comprehensive information on the Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3
The report reviews Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics and enlists all their major and minor projects
The report assesses Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Integrin Beta 3 Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeNEXT ARTICLE
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells. In vertebrates, it is composed of blo...